Mar 4, 2026 09:17AM Harrow Health (HROW) PT Lowered to $91 at Cantor Fitzgerald

Mar 4, 2026 06:43AM Harrow Health (HROW) PT Raised to $70 at H.C. Wainwright

Mar 3, 2026 03:15PM William Blair Reiterates Outperform Rating on Harrow Health (HROW): "We believe the long-term growth outlook is attractive"

Mar 2, 2026 04:10PM Harrow Health (HROW) Misses Q4 EPS by 22c, provides guidance

Feb 4, 2026 06:48AM B.Riley Reiterates Buy Rating on Harrow Health (HROW)

Feb 2, 2026 07:02AM Harrow reaffirms 2025 revenue guidance of $270-280 million

Nov 18, 2025 07:01AM Harrow completes acquisition of Melt Pharmaceuticals for sedation therapies

Nov 10, 2025 04:13PM Harrow Health (HROW) Tops Q3 EPS by 9c

Sep 29, 2025 06:59AM H.C. Wainwright Reiterates Buy Rating on Harrow Health (HROW)

Sep 25, 2025 04:06PM Harrow launches patient access program for ophthalmic portfolio

Sep 23, 2025 06:45AM Harrow Health (HROW) PT Raised to $70 at B.Riley

Aug 14, 2025 05:34AM Harrow Health (HROW) PT Raised to $63 at BTIG

Aug 13, 2025 06:55AM Harrow Health (HROW) PT Raised to $64 at H.C. Wainwright

Aug 11, 2025 04:02PM Harrow Health (HROW) Tops Q2 EPS by 23c, Misses on Revenue

Jul 18, 2025 08:26AM Cantor Fitzgerald Reiterates Overweight Rating on Harrow Health (HROW)

Jul 18, 2025 06:54AM H.C. Wainwright Reiterates Buy Rating on Harrow Health (HROW)

Jul 17, 2025 07:00AM Harrow secures exclusive US rights to Samsung Bioepis eye biosimilars

Jul 11, 2025 06:45AM Cantor Fitzgerald Starts Harrow Health (HROW) at Overweight

Jun 11, 2025 04:25PM BTIG Starts Harrow Health (HROW) at Buy

Jun 10, 2025 05:58AM William Blair Starts Harrow Health (HROW) at Outperform

Jun 9, 2025 07:03AM Harrow Health (HROW) Acquires U.S. Commercial Rights to BYQLOVI

May 12, 2025 06:57AM Harrow Health (HROW) PT Raised to $60 at H.C. Wainwright

May 8, 2025 04:03PM Harrow Health (HROW) Misses Q1 EPS by 56c

Mar 31, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Harrow Health (HROW)

Mar 24, 2025 07:05AM Harrow Health (HROW) Announces Transitional Pass-Through Reimbursement Status for TRIESENCE 40 mg/mL

Mar 19, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Harrow Health (HROW)

Mar 18, 2025 03:03PM Harrow Health (HROW) March 22 puts and April 35 calls active as share price up 15%

Feb 6, 2025 08:44AM H.C. Wainwright Starts Harrow Health (HROW) at Buy

Jan 7, 2025 07:01AM Harrow Health (HROW) Appoints Amir H. Shojaei as Chief Scientific Officer

Nov 21, 2024 07:02AM Harrow Health (HROW) ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Nov 13, 2024 04:36PM Harrow Health (HROW) Misses Q3 EPS by 7c

Nov 12, 2024 07:07AM Harrow Health (HROW) Announces Market Access Wins for VEVYE

Oct 18, 2024 06:10AM Harrow Health (HROW) PT Raised to $73 at B.Riley

Oct 3, 2024 07:02AM Harrow Health (HROW) Relaunches TRIESENCE

Sep 25, 2024 12:02PM Harrow Health (HROW) Announces Nashville Expansion

Aug 7, 2024 04:55PM Harrow Health (HROW) Tops Q2 EPS by 12c

Jul 9, 2024 07:02AM Harrow Health (HROW) Enters into 340B Prime Vendor Program Contract with Apexus for IHEEZO

Jun 21, 2024 08:34AM Harrow Health (HROW) PT Raised to $30 at Craig-Hallum

Jun 20, 2024 07:04AM Harrow Health (HROW) Provides TRIESENCE Relaunch Update